The effects of apoptosis inhibitor of macrophage in kidney diseases.

Apoptosis inhibitor of macrophages Chronic kidney disease Kidney diseases

Journal

European journal of medical research
ISSN: 2047-783X
Titre abrégé: Eur J Med Res
Pays: England
ID NLM: 9517857

Informations de publication

Date de publication:
04 Jan 2024
Historique:
received: 27 08 2023
accepted: 14 12 2023
medline: 5 1 2024
pubmed: 5 1 2024
entrez: 4 1 2024
Statut: epublish

Résumé

Kidney disease is a progressive and irreversible condition in which immunity is a contributing factor that endangers human health. It is widely acknowledged that macrophages play a significant role in developing and causing numerous kidney diseases. The increasing focus on the mechanism by which macrophages express apoptosis inhibitor of macrophages (AIM) in renal diseases has been observed. AIM is an apoptosis inhibitor that stops different things that cause apoptosis from working. This keeps AIM-bound cell types alive. Notably, the maintenance of immune cell viability regulates immunity. As our investigation progressed, we concluded that AIM has two sides when it comes to renal diseases. AIM can modulate renal phagocytosis, expedite the elimination of renal tubular cell fragments, and mitigate tissue injury. AIM can additionally exacerbate the development of renal fibrosis and kidney disease by prolonging inflammation. IgA nephropathy (IgAN) may also worsen faster if more protein is in the urine. This is because IgA and immunoglobulin M are found together and expressed. In the review, we provide a comprehensive overview of prior research and concentrate on the impacts of AIM on diverse subcategories of nephropathies. We discovered that AIM is closely associated with renal diseases by playing a positive or negative role in the onset, progression, or cure of kidney disease. AIM is thus a potentially effective therapeutic target for kidney diseases.

Identifiants

DOI: 10.1186/s40001-023-01597-3 PMID: 38178221
pubmed: 38178221
doi: 10.1186/s40001-023-01597-3
pii: 10.1186/s40001-023-01597-3
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

21

Subventions

Organisme : Foundation of Key R&D plan of Sichuan Province
ID : 2019YFS0538
Organisme : National Natural Science Foundation of China
ID : 82200810

Informations de copyright

© 2023. The Author(s).

Références

Zhang L, Wang F, Wang L, Wang W, Liu B, Liu J, Chen M, He Q, Liao Y, Yu X, Chen N, Zhang J-e, Hu Z, Liu F, Hong D, Ma L, Liu H, Zhou X, Chen J, Pan L, Chen W, Wang W, Li X, Wang H. Prevalence of chronic kidney disease in China: a cross-sectional survey. The Lancet. 2012;379:815–22. https://doi.org/10.1016/s0140-6736(12)60033-6 .
doi: 10.1016/s0140-6736(12)60033-6
Misra A, Tandon N, Ebrahim S, Sattar N, Alam D, Shrivastava U, Narayan KM, Jafar TH. Diabetes, cardiovascular disease, and chronic kidney disease in South Asia: current status and future directions. BMJ. 2017;357:j1420. https://doi.org/10.1136/bmj.j1420 .
doi: 10.1136/bmj.j1420 pubmed: 28400361
Martinez VG, Escoda-Ferran C, Tadeu Simoes I, Arai S, Orta Mascaro M, Carreras E, Martinez-Florensa M, Yelamos J, Miyazaki T, Lozano F. The macrophage soluble receptor AIM/Api6/CD5L displays a broad pathogen recognition spectrum and is involved in early response to microbial aggression. Cell Mol Immunol. 2014;11:343–54. https://doi.org/10.1038/cmi.2014.12 .
doi: 10.1038/cmi.2014.12 pubmed: 24583716 pmcid: 4085514
Arai S, Miyazaki T. A scavenging system against internal pathogens promoted by the circulating protein apoptosis inhibitor of macrophage (AIM). Semin Immunopathol. 2018;40:567–75. https://doi.org/10.1007/s00281-018-0717-6 .
doi: 10.1007/s00281-018-0717-6 pubmed: 30310974 pmcid: 6223838
Uchida M, Uchida K, Maeda S, Yonezawa T. Expression of apoptosis inhibitor of macrophages in tissue macrophages, leukocytes and vascular endothelial cells of dogs. Tissue Cell. 2019;58:112–20. https://doi.org/10.1016/j.tice.2019.05.002 .
doi: 10.1016/j.tice.2019.05.002 pubmed: 31133238
Miyazaki T, Hirokami Y, Matsuhashi N, Takatsuka H, Naito M. Increased susceptibility of thymocytes to apoptosis in mice lacking AIM, a novel murine macrophage-derived soluble factor belonging to the scavenger receptor cysteine-rich domain superfamily. J Exp Med. 1999. https://doi.org/10.1084/jem.189.2.413 .
doi: 10.1084/jem.189.2.413 pubmed: 9892623 pmcid: 2192994
You Q, Wu Y, Yao N, Shen G, Zhang Y, Xu L, Li G, Ju C. Interaction of AIM with insulin-like growth factor-binding protein-4. Int J Mol Med. 2015;36:833–8. https://doi.org/10.3892/ijmm.2015.2262 .
doi: 10.3892/ijmm.2015.2262 pubmed: 26135353 pmcid: 4533773
Sanjurjo L, Amezaga N, Aran G, Naranjo-Gomez M, Arias L, Armengol C, Borras FE, Sarrias MR. The human CD5L/AIM-CD36 axis: A novel autophagy inducer in macrophages that modulates inflammatory responses. Autophagy. 2015;11:487–502. https://doi.org/10.1080/15548627.2015.1017183 .
doi: 10.1080/15548627.2015.1017183 pubmed: 25713983 pmcid: 4502645
Miyazaki T, Kurokawa J, Arai S. AIMing at metabolic syndrome. -Towards the development of novel therapies for metabolic diseases via apoptosis inhibitor of macrophage (AIM). Circ J. 2011;75:2522–31. https://doi.org/10.1253/circj.cj-11-0891 .
doi: 10.1253/circj.cj-11-0891 pubmed: 21970839
Blandino R, Baumgarth N. Secreted IgM: new tricks for an old molecule. J Leukoc Biol. 2019;106:1021–34. https://doi.org/10.1002/JLB.3RI0519-161R .
doi: 10.1002/JLB.3RI0519-161R pubmed: 31302940
Gong S, Ruprecht RM. Immunoglobulin M: an ancient antiviral weapon–rediscovered. Front Immunol. 2020;11:1943. https://doi.org/10.3389/fimmu.2020.01943 .
doi: 10.3389/fimmu.2020.01943 pubmed: 32849652 pmcid: 7432194
Hiramoto E, Tsutsumi A, Suzuki R, Matsuoka S, Arai S, Kikkawa M and Miyazaki T (2018) The IgM pentamer is an asymmetric pentagon with an open groove that binds the AIM protein. Sci. Adv 4.
Miyazaki T, Yamazaki T, Sugisawa R, Gershwin ME, Arai S. AIM associated with the IgM pentamer: attackers on stand-by at aircraft carrier. Cell Mol Immunol. 2018;15:563–74. https://doi.org/10.1038/cmi.2017.141 .
doi: 10.1038/cmi.2017.141 pubmed: 29375122 pmcid: 6078943
Niles MJ, Matsuuchi L, Koshland ME. Polymer IgM assembly and secretion in lymphoid and nonlymphoid cell lines: evidence that J chain is required for pentamer IgM synthesis. Proc Natl Acad Sci USA. 1995;92:2884–8.
doi: 10.1073/pnas.92.7.2884 pubmed: 7708742 pmcid: 42323
Davis AC, Roux KH, Pursey J, Shulman MJ. Intermolecular disulfide bonding in IgM: effects of replacing cysteine residues in the mu heavy chain. EMBO J. 1989;8:2519–26.
doi: 10.1002/j.1460-2075.1989.tb08389.x pubmed: 2511005 pmcid: 401247
Ja GEBE, LLEWELLYN M-BC, HOGGATT H and ARUFFO A,. Molecular cloning, genomic organization and cell-binding characteristics of mouse Spa. Immunology. 2000;99:78–86.
doi: 10.1046/j.1365-2567.2000.00903.x
Yamazaki T, Sugisawa R, Hiramoto E, Takai R, Matsumoto A, Senda Y, Nakashima K, Nelson PS, Lucas JM, Morgan A, Li Z, Yamamura KI, Arai S, Miyazaki T. A proteolytic modification of AIM promotes its renal excretion. Sci Rep. 2016;6:38762. https://doi.org/10.1038/srep38762 .
doi: 10.1038/srep38762 pubmed: 27929116 pmcid: 5144010
Iannaccone A, Hollingsworth TJ, Koirala D, New DD, Lenchik NI, Beranova-Giorgianni S, Gerling IC, Radic MZ, Giorgianni F. Retinal pigment epithelium and microglia express the CD5 antigen-like protein, a novel autoantigen in age-related macular degeneration. Exp Eye Res. 2017;155:64–74. https://doi.org/10.1016/j.exer.2016.12.006 .
doi: 10.1016/j.exer.2016.12.006 pubmed: 27989757
Bamodu OA, Wang YH, Yeh CT, Ho CH, Chiang YT, Kao WT, Liu CH, Wu CC. Concomitant high apoptosis inhibitor of macrophage (AIM) and Low Prostate-Specific Antigen (PSA) indicates activated t cell-mediated anticancer immunity, enhance sensitivity to pembrolizumab, and elicit good prognosis in prostate cancer. Biomedicines. 2021. https://doi.org/10.3390/biomedicines9091225 .
doi: 10.3390/biomedicines9091225 pubmed: 34944649 pmcid: 8698269
Gao X, Liu Y, Xu F, Lin S, Song Z, Duan J, Yin Y, Cao J. Assessment of apoptosis inhibitor of macrophage/CD5L as a Biomarker to predict mortality in the critically Ill with sepsis. Chest. 2019;156:696–705. https://doi.org/10.1016/j.chest.2019.04.134 .
doi: 10.1016/j.chest.2019.04.134 pubmed: 31154043
Gao X, Yan X, Yin Y, Lin X, Zhang Q, Xia Y, Cao J. Therapeutic Targeting of apoptosis inhibitor of macrophage/CD5L in sepsis. Am J Respir Cell Mol Biol. 2019;60:323–34. https://doi.org/10.1165/rcmb.2018-0272OC .
doi: 10.1165/rcmb.2018-0272OC pubmed: 30326743
Ono Y, Kanmura S, Morinaga Y, Oda K, Kawabata K, Arima S, Sasaki F, Nasu Y, Tanoue S, Hashimoto S, Taguchi H, Uto H, Tsubouchi H, Ido A. The utility of apoptosis inhibitor of macrophages as a possible diagnostic marker in patients with Crohn’s disease. BMC Gastroenterol. 2017;17:40. https://doi.org/10.1186/s12876-017-0591-z .
doi: 10.1186/s12876-017-0591-z pubmed: 28284201 pmcid: 5346245
Shimizu T, Sawada T, Asai T, Kanetsuki Y, Hirota J, Moriguchi M, Nakajima T, Miyazaki T, Okanoue T. Hepatocellular carcinoma diagnosis using a novel electrochemiluminescence immunoassay targeting serum IgM-free AIM. Clin J Gastroenterol. 2022;15:41–51. https://doi.org/10.1007/s12328-021-01567-4 .
doi: 10.1007/s12328-021-01567-4 pubmed: 34981443 pmcid: 8858287
Kojima J, Araya J, Hara H, Ito S, Takasaka N, Kobayashi K, Fujii S, Tsurushige C, Numata T, Ishikawa T, Shimizu K, Kawaishi M, Saito K, Kamiya N, Hirano J, Odaka M, Morikawa T, Hano H, Arai S, Miyazaki T, Kaneko Y, Nakayama K, Kuwano. Apoptosis inhibitor of macrophage (AIM) expression in alveolar macrophages in COPD. Respir Res. 2013. https://doi.org/10.1186/1465-9921-14-30 .
doi: 10.1186/1465-9921-14-30 pubmed: 23725215 pmcid: 3674977
Nishikido T, Oyama J, Shiraki A, Komoda H, Node K. Deletion of Apoptosis Inhibitor of Macrophage (AIM)/CD5L attenuates the inflammatory response and infarct size in acute myocardial infarction. J Am Heart Assoc. 2016;5:e002863. https://doi.org/10.1161/JAHA.115.002863 .
doi: 10.1161/JAHA.115.002863 pubmed: 27045005 pmcid: 4859278
Kimura H, Suzuki M, Konno S, Shindou H, Shimizu T, Nagase T, Miyazaki T, Nishimura M. Orchestrating role of apoptosis inhibitor of macrophage in the resolution of acute lung injury. J Immunol. 2017;199:3870–82. https://doi.org/10.4049/jimmunol.1601798 .
doi: 10.4049/jimmunol.1601798 pubmed: 29070674
Tang C, Han H, Yan M, Zhu S, Liu J, Liu Z, He L, Tan J, Liu Y, Liu H, Sun L, Duan S, Peng Y, Liu F, Yin XM, Zhang Z, Dong Z. PINK1-PRKN/PARK2 pathway of mitophagy is activated to protect against renal ischemia-reperfusion injury. Autophagy. 2018;14:880–97. https://doi.org/10.1080/15548627.2017.1405880 .
doi: 10.1080/15548627.2017.1405880 pubmed: 29172924 pmcid: 6070003
Krishnamoorthy A, Ajay AK, Hoffmann D, Kim T-M, Ramirez V, Campanholle G, Bobadilla NA, Waikar SS, Vaidya VS. Fibrinogen β-derived Bβ(15–42) peptide protects against kidney ischemia/reperfusion injury. Blood. 2011;118:1934–42. https://doi.org/10.1182/blood-2011-02-338061 .
doi: 10.1182/blood-2011-02-338061 pubmed: 21685370 pmcid: 3158721
Arai S, Kitada K, Yamazaki T, Takai R, Zhang X, Tsugawa Y, Sugisawa R, Matsumoto A, Mori M, Yoshihara Y, Doi K, Maehara N, Kusunoki S, Takahata A, Noiri E, Suzuki Y, Yahagi N, Nishiyama A, Gunaratnam L, Takano T, Miyazaki T. Apoptosis inhibitor of macrophage protein enhances intraluminal debris clearance and ameliorates acute kidney injury in mice. Nat Med. 2016;22:183–93. https://doi.org/10.1038/nm.4012 .
doi: 10.1038/nm.4012 pubmed: 26726878
Ichimura T, Asseldonk EJ, Humphreys BD, Gunaratnam L, Duffield JS, Bonventre JV. Kidney injury molecule-1 is a phosphatidylserine receptor that confers a phagocytic phenotype on epithelial cells. J Clin Invest. 2008;118:1657–68. https://doi.org/10.1172/JCI34487 .
doi: 10.1172/JCI34487 pubmed: 18414680 pmcid: 2293335
Yang L, Brooks CR, Xiao S, Sabbisetti V, Yeung MY, Hsiao LL, Ichimura T, Kuchroo V, Bonventre JV. KIM-1-mediated phagocytosis reduces acute injury to the kidney. J Clin Invest. 2015;125:1620–36. https://doi.org/10.1172/JCI75417 .
doi: 10.1172/JCI75417 pubmed: 25751064 pmcid: 4396492
Ismail OZ, Zhang X, Bonventre JV, Gunaratnam L. G protein alpha12 (Galpha12) is a negative regulator of kidney injury molecule-1-mediated efferocytosis. Am J Physiol Renal Physiol. 2016;310:F607–20. https://doi.org/10.1152/ajprenal.00169.2015 .
doi: 10.1152/ajprenal.00169.2015 pubmed: 26697979
Al-Bataineh MM, Kinlough CL, Mi Z, Jackson EK, Mutchler SM, Emlet DR, Kellum JA, Hughey RP. KIM-1-mediated anti-inflammatory activity is preserved by MUC1 induction in the proximal tubule during ischemia-reperfusion injury. Am J Physiol Renal Physiol. 2021;321:F135–48. https://doi.org/10.1152/ajprenal.00127.2021 .
doi: 10.1152/ajprenal.00127.2021 pubmed: 34151589 pmcid: 8424662
Ajay AK, Kim T-M, Ramirez-Gonzalez V, Park PJ, Frank DA, Vaidya VS. A bioinformatics approach identifies signal transducer and activator of transcription-3 and checkpoint kinase 1 as upstream regulators of kidney injury molecule-1 after kidney injury. J Am Soc Nephrol. 2014;25:105–18. https://doi.org/10.1681/ASN.2013020161 .
doi: 10.1681/ASN.2013020161 pubmed: 24158981
Allison SJ. Acute kidney injury: AIMing to enhance debris clearance and improve outcomes in AKI. Nat Rev Nephrol. 2016;12:123. https://doi.org/10.1038/nrneph.2016.3 .
doi: 10.1038/nrneph.2016.3 pubmed: 26782147
Kurokawa J, Arai S, Nakashima K, Nagano H, Nishijima A, Miyata K, Ose R, Mori M, Kubota N, Kadowaki T, Oike Y, Koga H, Febbraio M, Iwanaga T, Miyazaki T. Macrophage-derived AIM is endocytosed into adipocytes and decreases lipid droplets via inhibition of fatty acid synthase activity. Cell Metab. 2010;11:479–92. https://doi.org/10.1016/j.cmet.2010.04.013 .
doi: 10.1016/j.cmet.2010.04.013 pubmed: 20519120
Sanchez-Rodriguez MB, Tellez E, Casulleras M, Borras FE, Arroyo V, Claria J, Sarrias MR. Reduced plasma extracellular vesicle CD5L content in patients with acute-on-chronic liver failure: interplay with specialized pro-resolving lipid mediators. Front Immunol. 2022;13:842996. https://doi.org/10.3389/fimmu.2022.842996 .
doi: 10.3389/fimmu.2022.842996 pubmed: 35330909 pmcid: 8940329
de Menezes-Neto A, Saez MJ, Lozano-Ramos I, Segui-Barber J, Martin-Jaular L, Ullate JM, Fernandez-Becerra C, Borras FE, Del Portillo HA. Size-exclusion chromatography as a stand-alone methodology identifies novel markers in mass spectrometry analyses of plasma-derived vesicles from healthy individuals. J Extracell Vesicles. 2015;4:27378. https://doi.org/10.3402/jev.v4.27378 .
doi: 10.3402/jev.v4.27378 pubmed: 26154623
Chartier MJ, Tangri N, Komenda P, Walld R, Koseva I, Burchill C, McGowan KL, Dart A. Prevalence, socio-demographic characteristics, and comorbid health conditions in pre-dialysis chronic kidney disease: results from the Manitoba chronic kidney disease cohort. BMC Nephrol. 2018;19:255. https://doi.org/10.1186/s12882-018-1058-3 .
doi: 10.1186/s12882-018-1058-3 pubmed: 30305038 pmcid: 6180583
Lambert K, Lau TK, Davison S, Mitchell H, Harman A, Carrie M. Development and preliminary results on the feasibility of a renal diet specific question prompt sheet for use in nephrology clinics. BMC Nephrol. 2019;20:48. https://doi.org/10.1186/s12882-019-1231-3 .
doi: 10.1186/s12882-019-1231-3 pubmed: 30755163 pmcid: 6373020
Leung KCW, Tonelli M, James MT. Chronic kidney disease following acute kidney injury-risk and outcomes. Nat Rev Nephrol. 2013;9:77–85. https://doi.org/10.1038/nrneph.2012.280 .
doi: 10.1038/nrneph.2012.280 pubmed: 23247572
Forni LG, Darmon M, Ostermann M, Oudemans-van Straaten HM, Pettila V, Prowle JR, Schetz M, Joannidis M. Renal recovery after acute kidney injury. Intensive Care Med. 2017;43:855–66. https://doi.org/10.1007/s00134-017-4809-x .
doi: 10.1007/s00134-017-4809-x pubmed: 28466146 pmcid: 5487594
Sugisawa R, Komatsu G, Hiramoto E, Takeda N, Yamamura KI, Arai S, Miyazaki T. Independent modes of disease repair by AIM protein distinguished in AIM-felinized mice. Sci Rep. 2018;8:13157. https://doi.org/10.1038/s41598-018-31580-6 .
doi: 10.1038/s41598-018-31580-6 pubmed: 30177770 pmcid: 6120884
Garofalo C, Borrelli S, Minutolo R, Chiodini P, De Nicola L, Conte G. A systematic review and meta-analysis suggests obesity predicts onset of chronic kidney disease in the general population. Kidney Int. 2017;91:1224–35. https://doi.org/10.1016/j.kint.2016.12.013 .
doi: 10.1016/j.kint.2016.12.013 pubmed: 28187985
Sanjurjo L, Aran G, Roher N, Valledor AF, Sarrias MR. AIM/CD5L: a key protein in the control of immune homeostasis and inflammatory disease. J Leukoc Biol. 2015;98:173–84. https://doi.org/10.1189/jlb.3RU0215-074R .
doi: 10.1189/jlb.3RU0215-074R pubmed: 26048980
Iwamura Y, Mori M, Nakashima K, Mikami T, Murayama K, Arai S, Miyazaki T. Apoptosis inhibitor of macrophage (AIM) diminishes lipid droplet-coating proteins leading to lipolysis in adipocytes. Biochem Biophys Res Commun. 2012;422:476–81. https://doi.org/10.1016/j.bbrc.2012.05.018 .
doi: 10.1016/j.bbrc.2012.05.018 pubmed: 22579686
Kai T, Yamazaki T, Arai S, Miyazaki T. Stabilization and augmentation of circulating AIM in mice by synthesized IgM-Fc. PLoS ONE. 2014;9: e97037. https://doi.org/10.1371/journal.pone.0097037 .
doi: 10.1371/journal.pone.0097037 pubmed: 24804991 pmcid: 4013091
Arai S, Maehara N, Iwamura Y, Honda S, Nakashima K, Kai T, Ogishi M, Morita K, Kurokawa J, Mori M, Motoi Y, Miyake K, Matsuhashi N, Yamamura K, Ohara O, Shibuya A, Wakeland EK, Li QZ, Miyazaki T. Obesity-associated autoantibody production requires AIM to retain the immunoglobulin M immune complex on follicular dendritic cells. Cell Rep. 2013;3:1187–98. https://doi.org/10.1016/j.celrep.2013.03.006 .
doi: 10.1016/j.celrep.2013.03.006 pubmed: 23562157
Kurokawa J, Nagano H, Ohara O, Kubota N, Kadowaki T, Arai S, Miyazaki T. Apoptosis inhibitor of macrophage (AIM) is required for obesity-associated recruitment of inflammatory macrophages into adipose tissue. Proc Natl Acad Sci U S A. 2011;108:12072–7. https://doi.org/10.1073/pnas.1101841108 .
doi: 10.1073/pnas.1101841108 pubmed: 21730133 pmcid: 3141977
Arai S, Miyazaki T. Impacts of the apoptosis inhibitor of macrophage (AIM) on obesity-associated inflammatory diseases. Semin Immunopathol. 2014;36:3–12. https://doi.org/10.1007/s00281-013-0405-5 .
doi: 10.1007/s00281-013-0405-5 pubmed: 24281248
Kim TH, Yang K, Kim M, Kim HS, Kang JL. Apoptosis inhibitor of macrophage (AIM) contributes to IL-10-induced anti-inflammatory response through inhibition of inflammasome activation. Cell Death Dis. 2021;12:19. https://doi.org/10.1038/s41419-020-03332-w .
doi: 10.1038/s41419-020-03332-w pubmed: 33414479 pmcid: 7791024
Tomita T, Arai S, Kitada K, Mizuno M, Suzuki Y, Sakata F, Nakano D, Hiramoto E, Takei Y, Maruyama S, Nishiyama A, Matsuo S, Miyazaki T, Ito Y. Apoptosis inhibitor of macrophage ameliorates fungus-induced peritoneal injury model in mice. Sci Rep. 2017;7:6450. https://doi.org/10.1038/s41598-017-06824-6 .
doi: 10.1038/s41598-017-06824-6 pubmed: 28743989 pmcid: 5527077
Uramatsu T, Nishino T, Obata Y, Sato Y, Furusu A, Koji T, Miyazaki T, Kohnoa S. Involvement of apoptosis inhibitor of macrophages in a rat hypertension model with ephrosclerosis: possible mechanisms of action of olmesartan and azelnidipine. Biol Pharm Bull. 2013;36(8):1271–7.
doi: 10.1248/bpb.b12-00965 pubmed: 23902971
Amezaga N, Sanjurjo L, Julve J, Aran G, Perez-Cabezas B, Bastos-Amador P, Armengol C, Vilella R, Escola-Gil JC, Blanco-Vaca F, Borras FE, Valledor AF, Sarrias MR. Human scavenger protein AIM increases foam cell formation and CD36-mediated oxLDL uptake. J Leukoc Biol. 2014;95:509–20. https://doi.org/10.1189/jlb.1212660 .
doi: 10.1189/jlb.1212660 pubmed: 24295828
Mori M, Kimura H, Iwamura Y, Arai S, Miyazaki T. Modification of N-glycosylation modulates the secretion and lipolytic function of apoptosis inhibitor of macrophage (AIM). FEBS Lett. 2012;586:3569–74. https://doi.org/10.1016/j.febslet.2012.08.017 .
doi: 10.1016/j.febslet.2012.08.017 pubmed: 23236605
Chen J, Liu Q, He J, Li Y. Immune responses in diabetic nephropathy: pathogenic mechanisms and therapeutic target. Front Immunol. 2022;13:958790. https://doi.org/10.3389/fimmu.2022.958790 .
doi: 10.3389/fimmu.2022.958790 pubmed: 36045667 pmcid: 9420855
Zhuang L, Jin G, Hu X, Yang Q, Shi Z. The inhibition of SGK1 suppresses epithelial-mesenchymal transition and promotes renal tubular epithelial cell autophagy in diabetic nephropathy. Am J Transl Res. 2019;11:4946–56.
pubmed: 31497211 pmcid: 6731399
Bringans S, Peters K, Casey T, Ito J, Lipscombe R. The new and the old: platform cross-validation of immunoaffinity MASS spectrometry versus ELISA for PromarkerD, a predictive test for diabetic kidney disease. Proteomes. 2020. https://doi.org/10.3390/proteomes8040031 .
doi: 10.3390/proteomes8040031 pubmed: 33126588 pmcid: 7709118
Peters KE, Davis WA, Ito J, Winfield K, Stoll T, Bringans SD, Lipscombe RJ, Davis TME. Identification of novel circulating biomarkers predicting rapid decline in renal function in type 2 diabetes: the fremantle diabetes study phase II. Diabetes Care. 2017;40:1548–55. https://doi.org/10.2337/dc17-0911 .
doi: 10.2337/dc17-0911 pubmed: 28851702
Chow F, Ozols E, Nikolic-Paterson DJ, Atkins RC, Tesch GH. Macrophages in mouse type 2 diabetic nephropathy: correlation with diabetic state and progressive renal injury. Kidney Int. 2004;65:116–28.
doi: 10.1111/j.1523-1755.2004.00367.x pubmed: 14675042
Davis TME, Peters KE, Lipscombe R. Apoptosis inhibitor of macrophage and diabetic kidney disease. Cell Mol Immunol. 2019;16:521. https://doi.org/10.1038/s41423-018-0088-x .
doi: 10.1038/s41423-018-0088-x pubmed: 30002449
Davis TME, Peters KE, Lipscombe R. Apoptosis inhibitor of macrophage and diabetic kidney disease. Cell Mol Immunol. 2018;16:521–521. https://doi.org/10.1038/s41423-018-0088-x .
doi: 10.1038/s41423-018-0088-x pubmed: 30002449 pmcid: 6474206
Davis TME, Chubb SAP, Davis WA. The relationship between estimated glomerular filtration rate trajectory and all-cause mortality in type 2 diabetes: the Fremantle Diabetes Study. Eur J Endocrinol. 2016;175:273–85. https://doi.org/10.1530/EJE-16-0327 .
doi: 10.1530/EJE-16-0327 pubmed: 27418062
Zambrano S, He L, Kano T, Sun Y, Charrin E, Lal M, Betsholtz C, Suzuki Y, Patrakka J. Molecular insights into the early stage of glomerular injury in IgA nephropathy using single-cell RNA sequencing. Kidney Int. 2022;101:752–65. https://doi.org/10.1016/j.kint.2021.12.011 .
doi: 10.1016/j.kint.2021.12.011 pubmed: 34968552
Zhang H, Barratt J. Is IgA nephropathy the same disease in different parts of the world? Semin Immunopathol. 2021;43:707–15. https://doi.org/10.1007/s00281-021-00884-7 .
doi: 10.1007/s00281-021-00884-7 pubmed: 34417628
Takahata A, Arai S, Hiramoto E, Kitada K, Kato R, Makita Y, Suzuki H, Nakata J, Araki K, Miyazaki T, Suzuki Y. Crucial role of AIM/CD5L in the development of glomerular inflammation in IgA nephropathy. J Am Soc Nephrol. 2020;31:2013–24. https://doi.org/10.1681/ASN.2019100987 .
doi: 10.1681/ASN.2019100987 pubmed: 32611589 pmcid: 7461693
van Dixhoorn MG, Sato T, Muizert Y, van Gijlswijk-Janssen DJ, De Heer E, Daha MR. Combined glomerular deposition of polymeric rat IgA and IgG aggravates renal inflammation. Kidney Int. 2000;58:90–9.
doi: 10.1046/j.1523-1755.2000.00144.x pubmed: 10886553
Lee JY, Arumugarajah S, Lian D, Maehara N, Haig AR, Suri RS, Miyazaki T, Gunaratnam L. Recombinant apoptosis inhibitor of macrophage protein reduces delayed graft function in a murine model of kidney transplantation. PLoS ONE. 2021;16:e0249838. https://doi.org/10.1371/journal.pone.0249838 .
doi: 10.1371/journal.pone.0249838 pubmed: 33891625 pmcid: 8064555
Tepel M, Alkaff FF, Kremer D, Bakker SJL, Thaunat O, Nagarajah S, Saleh Q, Berger SP, van den Born J, Krogstrup NV, Nielsen MB, Norregaard R, Jespersen B, Sparding N, Genovese F, Karsdal MA, Rasmussen DGK. Pretransplant endotrophin predicts delayed graft function after kidney transplantation. Sci Rep. 2022;12:4079. https://doi.org/10.1038/s41598-022-07645-y .
doi: 10.1038/s41598-022-07645-y pubmed: 35260630 pmcid: 8904626
Callemeyn J, Lamarthee B, Koenig A, Koshy P, Thaunat O, Naesens M. Allorecognition and the spectrum of kidney transplant rejection. Kidney Int. 2022;101:692–710. https://doi.org/10.1016/j.kint.2021.11.029 .
doi: 10.1016/j.kint.2021.11.029 pubmed: 34915041
Oshima M, Iwata Y, Furuichi K, Sakai N, Shimizu M, Hara A, Kitajima S, Toyama T, Shinozaki Y, Sagara A, Umeda E, Kaneko S, Arai S, Miyazaki T, Wada T. Association of apoptosis inhibitor of macrophage (AIM) expression with urinary protein and kidney dysfunction. Clin Exp Nephrol. 2017;21:35–42. https://doi.org/10.1007/s10157-016-1240-5 .
doi: 10.1007/s10157-016-1240-5 pubmed: 26846784

Auteurs

Yixia Cao (Y)

School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Department of Nephrology, Sichuan Academy of Medical Science and Sichuan Provincial People's Hospital, Sichuan Renal Disease Clinical Research Center, University of Electronic Science and Technology of China, Chengdu, China.
Chinese Academy of Sciences Sichuan Translational Medicine Research Hospital, Chengdu, China.

Boyan Hu (B)

School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Department of Nephrology, Sichuan Academy of Medical Science and Sichuan Provincial People's Hospital, Sichuan Renal Disease Clinical Research Center, University of Electronic Science and Technology of China, Chengdu, China.
Chinese Academy of Sciences Sichuan Translational Medicine Research Hospital, Chengdu, China.

Yunhe Fan (Y)

Reproductive & Women-Children Hospital, School of Medical and Life Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu, China.

Wei Wang (W)

Department of Nephrology, Sichuan Academy of Medical Science and Sichuan Provincial People's Hospital, Sichuan Renal Disease Clinical Research Center, University of Electronic Science and Technology of China, Chengdu, China.
Chinese Academy of Sciences Sichuan Translational Medicine Research Hospital, Chengdu, China.

Mingxuan Chi (M)

Department of Nephrology, Sichuan Academy of Medical Science and Sichuan Provincial People's Hospital, Sichuan Renal Disease Clinical Research Center, University of Electronic Science and Technology of China, Chengdu, China.
Chinese Academy of Sciences Sichuan Translational Medicine Research Hospital, Chengdu, China.

Moussa Ide Nasser (MI)

Department of Cardiac Surgery, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Guangdong Cardiovascular Institute, Southern Medical University, Guangzhou, 510100, Guangdong, China. moussa@gdph.org.cn.

Kuai Ma (K)

Department of Nephrology, Osaka University Graduate School of Medicine, Osaka, Japan. ma-kuai@ncchd.go.jp.

Chi Liu (C)

Department of Nephrology, Sichuan Academy of Medical Science and Sichuan Provincial People's Hospital, Sichuan Renal Disease Clinical Research Center, University of Electronic Science and Technology of China, Chengdu, China. liuchi_1230@163.com.
Chinese Academy of Sciences Sichuan Translational Medicine Research Hospital, Chengdu, China. liuchi_1230@163.com.
Renal Department and Nephrology Institute, School of Medicine, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Sichuan Clinical Research Center for Kidney Diseases, Chengdu, China. liuchi_1230@163.com.

Classifications MeSH